<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Clinical Trial on goodinfo.net Daily</title>
    <link>https://goodinfo.net/en/tags/clinical-trial/</link>
    <description>goodinfo.net daily curated global news: AI, tech, finance, and world affairs.</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <author>goodinfo.net</author>
    
    
    
    <lastBuildDate>Fri, 22 May 2026 22:25:00 +0800</lastBuildDate>
    <atom:link href="https://goodinfo.net/en/tags/clinical-trial/index.xml" rel="self" type="application/rss+xml" />
    
    <item>
      <title>UK Scientists Developing Ebola Vaccine Ready for Trials in Months</title>
      <link>https://goodinfo.net/en/posts/health/uk-ebola-vaccine-trials-months-may-20260522/</link>
      <pubDate>Fri, 22 May 2026 22:25:00 +0800</pubDate>
      <author>goodinfo.net</author>
      <guid>https://goodinfo.net/en/posts/health/uk-ebola-vaccine-trials-months-may-20260522/</guid>
      <description>UK scientists are developing a vaccine for the current Ebola outbreak in the Democratic Republic of Congo, with clinical trials expected to begin within months.
The outbreak involves the rare Bundibugyo species of Ebola, which kills approximately one-third of those infected and has no approved vaccine. The WHO has upgraded its risk assessment, saying the outbreak is &ldquo;spreading rapidly.&rdquo;
In eastern DR Congo, angry crowds burned medical tents after being prevented from burying the body of a suspected Ebola victim, highlighting community resistance to containment measures.
</description>
      <content:encoded><![CDATA[<p>UK scientists are developing a vaccine for the current Ebola outbreak in the Democratic Republic of Congo, with clinical trials expected to begin within months.</p>
<p>The outbreak involves the rare Bundibugyo species of Ebola, which kills approximately one-third of those infected and has no approved vaccine. The WHO has upgraded its risk assessment, saying the outbreak is &ldquo;spreading rapidly.&rdquo;</p>
<p>In eastern DR Congo, angry crowds burned medical tents after being prevented from burying the body of a suspected Ebola victim, highlighting community resistance to containment measures.</p>
<p>If successful, the UK-developed vaccine would become a critical tool against the Bundibugyo strain. Vaccines for the more common Zaire strain have proven effective in past outbreaks, but Bundibugyo vaccine development remains in early stages.</p>
]]></content:encoded>
      <category domain="category">health</category>
      <category domain="tag">Ebola</category><category domain="tag">vaccine</category><category domain="tag">UK</category><category domain="tag">science</category><category domain="tag">clinical-trial</category>
    </item>
    
    <item>
      <title>Vitamin D Boosts Breast Cancer Treatment Success by 79%</title>
      <link>https://goodinfo.net/en/posts/science/vitamin-d-breast-cancer-chemotherapy-april-2026/</link>
      <pubDate>Wed, 29 Apr 2026 06:30:00 +0800</pubDate>
      <author>goodinfo.net</author>
      <guid>https://goodinfo.net/en/posts/science/vitamin-d-breast-cancer-chemotherapy-april-2026/</guid>
      <description>A clinical trial at São Paulo State University in Brazil found that a daily supplement of 2,000 IU vitamin D increased the rate of complete tumor disappearance after chemotherapy from 24% to 43%, suggesting an affordable intervention that warrants further investigation.</description>
      <content:encoded><![CDATA[<h2 id="-vitamin-d-boosts-breast-cancer-treatment-success-by-79">📰 Vitamin D Boosts Breast Cancer Treatment Success by 79%</h2>
<p>April 28, 2026 — Researchers at the Botucatu School of Medicine, São Paulo State University (FMB-UNESP) in Brazil, have published striking results from a clinical trial showing that a daily low-dose vitamin D supplement significantly improves chemotherapy outcomes in breast cancer patients. The study found that 43% of patients taking vitamin D achieved complete tumor disappearance after chemotherapy, compared to only 24% in the placebo group.</p>
<h3 id="study-design">Study Design</h3>
<p>The FAPESP-funded study enrolled 80 women over the age of 45 who were preparing to receive neoadjuvant chemotherapy (pre-surgical treatment designed to shrink tumors for easier surgical removal) at the oncology outpatient clinic of the university&rsquo;s teaching hospital.</p>
<p>Participants were randomly divided into two groups: the experimental group received a daily dose of 2,000 IU (international units) of vitamin D, while the control group received placebo tablets. All patients underwent standard neoadjuvant chemotherapy regimens.</p>
<h3 id="key-findings">Key Findings</h3>
<p>After six months of treatment, a notable difference emerged between the two groups:</p>
<ul>
<li><strong>Vitamin D group</strong>: 43% of patients achieved pathological complete response (pCR) — complete tumor disappearance following chemotherapy.</li>
<li><strong>Placebo group</strong>: Only 24% achieved the same result.</li>
</ul>
<p>&ldquo;Despite the small sample size, this result is encouraging,&rdquo; said one of the study&rsquo;s lead researchers. &ldquo;Vitamin D, as an inexpensive and widely available supplement, could have a profound impact on global breast cancer treatment if validated in larger clinical trials.&rdquo;</p>
<h3 id="scientific-mechanism">Scientific Mechanism</h3>
<p>Researchers hypothesize that vitamin D may enhance chemotherapy effectiveness through multiple mechanisms. First, vitamin D plays an important role in immune modulation, and many cancer patients are deficient in the vitamin. Second, vitamin D has been shown to influence cancer cell growth and differentiation processes, potentially making cancer cells more sensitive to chemotherapy drugs.</p>
<h3 id="caution-and-outlook">Caution and Outlook</h3>
<p>The research team emphasized the limitations of their findings. Due to the small sample size, these results need to be validated in larger, multi-center clinical trials. Additionally, it remains unclear what the optimal dosage, timing, and which patient subgroups would benefit most.</p>
<p>Nevertheless, given the low cost and high safety profile of vitamin D supplements, this study offers a highly promising avenue for improving breast cancer treatment outcomes.</p>
<hr>
<p><em>Source: <a href="https://www.sciencedaily.com/releases/2026/04/260428004119.htm">ScienceDaily</a></em></p>
]]></content:encoded>
      <category domain="category">science</category>
      <category domain="tag">vitamin D</category><category domain="tag">breast cancer</category><category domain="tag">chemotherapy</category><category domain="tag">clinical trial</category><category domain="tag">Brazil</category>
    </item>
    
  </channel>
</rss>
